No evidence for amplification of 25-hydroxyvitamin D-1α-OHase (1α-OHase) or 1,25-dihydroxyvitamin D-24-OHase (24-OHase) genes in malignant melanoma (MM)

Reichrath, Jörg; Rafi, Leyla; Rech, Martin; Meineke, Viktor; Tilgen, Wolfgang; Seifert, Markus

doi:10.1016/j.jsbmb.2004.03.096

Cited by 12 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the first report describing CYP27B1 in melanoma samples was published by Reichrath et al [35], although those authors analyzed only gene amplification using Southern blotting in 16 melanomas, and they did not find amplification of CYP27B1. In contrast, our studies, performed on a large panel of melanomas, showed a clear negative correlation between CYP27B1 protein expression and progression of cancer to more advanced stages.…”

Section: Discussionmentioning

confidence: 99%

Expression of the vitamin D–activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression

et al. 2013

View full text Add to dashboard Cite

Summary 1α-Hydroxylase (CYP27B1), the enzyme responsible for the synthesis of the biologically active form of vitamin D (1,25(OH)2D3), is expressed in the skin. To assess the correlation between progression of melanocytic tumors and CYP27B1, we analyzed its expression in 29 benign nevi, 75 primary cutaneous melanomas, 40 metastases, and 4 re-excision and 6 normal skin biopsies. Immunoreactivity for CYP27B1 was significantly lower in the vertical growth phase (VGP) and metastatic melanomas (0.6 and 0.5 arbitrary units [AU], respectively) in comparison with nevi and radial growth phase (RGP) tumors (1.2 and 1.1 AU, respectively); and expression was reduced in more advanced lesions (Clark levels III–V, Breslow thickness ≥2.1 mm; 0.8 and 0.7 AU, respectively). There was an inverse correlation between CYP27B1 and Ki-67 expression. Furthermore, CYP27B1 expression was reduced in primary melanomas that created metastases in comparison with non-metastasizing melanomas. Reduced CYP27B1 expression in RGP was related to shorter overall survival (810 vs 982 vs 1151 days in melanomas with absent, low, and high CYP27B1 immunoreactivity), and low CYP27B1 expression in RGP and VGP was related to shorter disease-free survival (114 vs 339 vs 737 days and 129 vs 307 vs 737 days, respectively, in melanomas with absent, low, and high CYP27B1). Also, CYP27B1 expression was inversely related to melanin in melanoma cells in vivo and melanoma cells cultured in vitro. Thus, reduction of CYP27B1 correlates with melanoma phenotype and behavior, and its lack affects the survival of melanoma patients, indicating a role in the pathogenesis and progression of this cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of the vitamin D–activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression

et al. 2013

View full text Add to dashboard Cite

show abstract

“…For melanoma cells as well as melanocytes, an anti-proliferative effect of 1,25(OH)2D3 in vitro has been shown [11, 45]. Reichrath et al [46] reported that the VDR receptor is expressed in primary melanoma tissue. Furthermore associations between reduced serum levels of 25-hydroxyvitamin D and cancer have been reported [20, 50, 51].…”

Section: Discussionmentioning

confidence: 99%

No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case–control study

et al. 2012

Self Cite

View full text Add to dashboard Cite

Melanoma is one of the most aggressive human cancers. The vitamin D system contributes to the pathogenesis and prognosis of malignancies including cutaneous melanoma. An expression of the vitamin D receptor (VDR) and an anti-proliferative effect of vitamin D in melanocytes and melanoma cells have been shown in vitro. Studies examining associations of polymorphisms in genes coding for vitamin D metabolism-related proteins (1α-hydroxylase [CYP27B1], 1,25(OH)2D-24hydroxylase [CYP24A1], vitamin D-binding protein [VDBP]) and cancer risk are scarce, especially with respect to melanoma. Mainly VDR polymorphisms regarding melanoma risk and prognosis were examined although other vitamin D metabolism-related genes may also be crucial. In our hospital-based case–control study including 305 melanoma patients and 370 healthy controls single nucleotide polymorphisms in the genes CYP27B1 (rs4646536), CYP24A1 (rs927650), VDBP (rs1155563, rs7041), and VDR (rs757343, rs731236, rs2107301, rs7975232) were analyzed for their association with melanoma risk and prognosis. Except VDR rs731236 and VDR rs2107301, the other six polymorphisms have not been analyzed regarding melanoma before. To further improve the prevention as well as the treatment of melanoma, it is important to identify further genetic markers for melanoma risk as well as prognosis in addition to the crude phenotypic, demographic, and environmental markers used in the clinic today. A panel of genetic risk markers could help to better identify individuals at risk for melanoma development or worse prognosis. We, however, found that none of the polymorphisms tested was associated with melanoma risk as well as prognosis in logistic and linear regression models in our study population.

show abstract

“…VDR expression has been detected in cultured melanoma cells, 41,45 melanoma xenographs, 46 and in primary melanoma tissue. 47 As with BCCs, VDR expression is stronger in melanoma cell lines than in normal melanocytes. 41 A recent large, international, multicenter, population-based, case control study has identified polymorphisms in the promoter, coding, and 3′ gene region of VDR that are significantly associated with melanoma after adjusting for relevant covariates.…”

Section: Role Of Vitamin D In Melanocytesmentioning

confidence: 96%

Vitamin D in cutaneous carcinogenesis

Tang

Lau

et al. 2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

The role of vitamin D in health maintenance and disease prevention in fields ranging from bone metabolism to cancer is currently under intensive investigation. A number of epidemiologic studies have suggested that vitamin D may have a protective effect on cancer risk and cancer-associated mortality. With regard to skin cancer, epidemiologic and laboratory studies suggest that vitamin D and its metabolites may have a similar risk reducing effect. Potential mechanisms of action include inhibition of the hedgehog signaling pathway and upregulation of nucleotide excision repair enzymes. The key factor complicating the association between vitamin D and skin cancer is ultraviolet B radiation. The same spectrum of ultraviolet B radiation that catalyzes the production of vitamin D in the skin also causes DNA damage that can lead to epidermal malignancies. Part II of this continuing medical education article will summarize the literature on vitamin D and skin cancer to identify evidence-based optimal serum levels of vitamin D and to recommend ways of achieving those levels while minimizing the risk of skin cancer.

show abstract

No evidence for amplification of 25-hydroxyvitamin D-1α-OHase (1α-OHase) or 1,25-dihydroxyvitamin D-24-OHase (24-OHase) genes in malignant melanoma (MM)

Cited by 12 publications

References 22 publications

Expression of the vitamin D–activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression

Expression of the vitamin D–activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression

No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case–control study

Vitamin D in cutaneous carcinogenesis

Contact Info

Product

Resources

About